The most dangerous cybersecurity assumption in a pre-commercial biotech company is that security operations can mature later after the next funding round, regulatory milestone, or first revenue.
That thinking is backward.
Commercialization does not create cyber risk. It exposes security debt accumulated while the business was moving quickly. The identities, cloud platforms, research systems, contractors, and privileged accounts already exist. What may not exist is an operating model capable of detecting a compromised identity at 11:47 p.m. and containing it before the attacker reaches something valuable.
For a biotech company, that is not merely an IT weakness. It is a valuation problem.
The Breach May Begin With a Normal Login
Leadership often imagines a serious cyberattack as ransomware appearing on every screen or a laboratory system suddenly going offline.
Identity compromise is more deceptive.
An attacker may enter through valid credentials. The login may come from an unusual location, a new device, a suspicious mailbox rule, or an abnormal privilege change. Because the attacker is using a real account, the activity can resemble ordinary work.
MITRE identifies valid accounts as a technique attackers use for initial access, persistence, privilege escalation, and defense evasion. CISA also emphasizes access-focused logging because organizations cannot respond effectively without visibility into identity and security events.
Now place that event at 11:47 p.m.
The IT director is asleep. The administrator is technically on call but has already worked a full day. The endpoint platform creates an alert. The identity platform creates another. The cloud platform records a third.
No one correlates them.
No one disables the session or checks whether the account accessed research data, changed permissions, downloaded files, or created a new authentication method.
The tools worked.
The operating model failed.
“We Have Alerts” Is Not a Security Strategy
Many pre-commercial biotechnology firms have endpoint detection, multifactor authentication, cloud logging, firewalls, backups, and perhaps a SIEM.
Leadership sees the invoices and assumes the company is covered.
But a security tool does not accept accountability.
A dashboard does not determine whether a researcher is working late or an attacker is using the researcher’s account. It does not decide containment authority, preserve evidence, or document what happened for an investor, insurer, auditor, partner, or regulator.
The real question is what happens during the first 15, 30, and 60 minutes after a meaningful alert appears.
Who acknowledges it?
Who investigates it?
Who can disable the account?
Who checks the cloud, endpoint, email, and privileged-access evidence?
Who wakes the appropriate executive when intellectual property may be exposed?
When the answer depends on one exhausted employee noticing a notification, the company does not have 24/7 security operations.
It has an after-hours hope strategy.
Commercialization Expands Exposure Before Revenue Arrives
Commercialization risk does not begin on launch day.
The company adds employees, vendors, consultants, contract research organizations, commercialization partners, and new applications. Data begins moving across more systems and relationships.
Access expands faster than security operations.
Privileges accumulate. Former contractors retain access. New applications are connected without clear monitoring or escalation procedures.
At the same time, partners begin asking harder questions. Insurers want evidence. Boards want confidence. Investors expect leadership to understand material operational risks.
The FBI notes that modern espionage is increasingly cyber-enabled and that trade secrets can be targeted through data theft from computer networks. For biotech leaders, the exposed assets may include research data, clinical information, manufacturing knowledge, intellectual property, strategic plans, or partner communications.
A single compromised identity can become the path into all of it.
The Real Damage Is Uncertainty
An identity compromise does not have to become a catastrophic breach to damage the business.
The incident may force leadership to pause systems, reset access, involve outside counsel, investigate third parties, brief the board, and answer uncomfortable questions from partners.
Research teams lose time. Commercial preparation slows. Executives are pulled away from launch priorities.
Worse, the company may be unable to reconstruct the incident because the right logs were never retained, correlated, or reviewed.
That is how immature security operations affect valuation: through uncertainty.
Leadership cannot confidently explain what was accessed, how long the account remained active, whether the attacker moved laterally, or whether sensitive data left the environment.
Uncertainty expands the incident.
It weakens investor, partner, and board confidence precisely when the company needs that confidence most.
SOC Maturity Is an Operating Capability, Not a Room
Biotech leaders often hear “SOC” and imagine an expensive internal facility staffed by a large team.
That false choice delays maturity. Leadership assumes the company must either build a full internal SOC or continue relying on the existing IT team.
Those are not the only options.
SOC maturity is defined by whether the company can consistently govern, identify, protect, detect, respond, and recover the six high-level functions within the NIST Cybersecurity Framework 2.0.
A managed or co-managed security model can provide capacity a lean internal team cannot reasonably create alone:
- Continuous monitoring
- Experienced investigation
- Documented escalation procedures
- After-hours coverage
- Contracted response expectations
- Repeatable reporting and evidence
Those expectations might include acknowledgement or investigation targets of 15 or 30 minutes for high-severity events.
The number alone is not the strategy. The accountability behind it matters more.
Leadership still owns the company’s risk. A managed model supplies trained capacity and continuous coverage that does not disappear when one employee is unavailable.
That is not a shortcut.
It is an operating decision.
Five Questions Leadership Must Answer
Before approving another security product, leadership should ask:
- Can we correlate identity, endpoint, email, cloud, and privileged-access activity after hours?
- Are response times contractually defined or merely described as “best effort”?
- Is containment authority documented before an incident occurs?
- Can we show what was investigated, escalated, decided, and remediated?
- Does coverage remain intact when internal employees are unavailable?
Weak answers do not necessarily mean the IT director failed.
They mean the operating model has outgrown the internal team’s capacity.
Do Not Let Commercialization Reveal the Gap
The wrong time to discover that security operations cannot support the business is during an active identity compromise, partner review, insurance renewal, or board discussion about launch readiness.
The useful next step is not another product demonstration.
It is a security operations assessment that tests how the company detects, investigates, escalates, and contains a realistic after-hours identity event.
Commercialization will place more pressure on every part of the business.
The uncomfortable question is whether security maturity is growing at the same speed or whether growth is simply making an old weakness harder to hide.
About Single Point of Contact
Single Point of Contact is an experienced MSP in the biotech industry and is a valuable partner, providing specialized knowledge in implementing robust backup strategies and ensuring network security and stability. With deep understanding of regulatory requirements such as HIPAA and FDA’s 21 CFR Part 11, Single Point of Contact safeguards sensitive research data, clinical trial information, and intellectual property. They offer tailored solutions, including automated backups, real-time monitoring, and disaster recovery plans, minimizing downtime and data loss. By managing security protocols, they protect against cyber threats, allowing biotech companies to focus on innovation while ensuring compliance and uninterrupted operations. This expertise enhances productivity and reduces risk. Contact us today to discover more about how we can help your biotech firm with DR, backup and security.
Biotech Podcast
On this podcast, we discuss data recovery. This episode explores the significant challenges biotech firms face in developing effective data recovery strategies. Topics include the importance of regular testing, rapid restoration capabilities, and the risks of inadequate planning. It highlights how speed and efficiency are crucial to uninterrupted operations, regulatory compliance, and maintaining trust in a data-driven industry. Tune in to the discussion.
Biotech YouTube
Subscribe to our YouTube channel. On a recent episode,” The Delay That Destroys Biotech”, Most biotech breaches aren’t discovered for months. And by the time they are, the damage is already done. In this episode, we break down what really happens during that silent window and why detection time, not prevention, defines your risk. If you can’t see it early, you can’t control it.
